Biotech News

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

Roche Holdings AG (RHHBY)Roche Holdings AG2026-10-19 05:00 ESTCompany update

Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid.

Related news

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

RHHBYRoche Holdings AG2026-10-09 05:00 EST

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

REGNRegeneron Pharmaceuticals2026-10-06 11:00 EST

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

ARGXArgenx2026-09-29 12:00 EST

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

SRPTSarepta Therapeutics2026-09-24 12:30 EST

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

BNTXBioNTech2026-10-22 10:45 EST

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

BNTXBioNTech2026-10-19 10:45 EST

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

GSKGSK plc2026-10-16 13:49 EST

GSK showcases pipeline momentum across lung, gynaecological and gastrointestinal cancers at ESMO 2026

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

CRSPCRISPR Therapeutics2026-10-08 12:30 EST

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

View all latest news

Roche Holdings AG

Integrated Pharmaceuticals and Diagnostics Company Roche is a global healthcare company that combines prescription medicines, diagnostic systems, and digital technologies within a single research and commercial organization. The group operates through Pharmaceuticals and Diagnostics divisions, with Genentech serving as its wholly owned...

Recent company news

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

RHHBYRoche Holdings AG2026-10-19 05:00 EST

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

RHHBYRoche Holdings AG2026-10-16 05:00 EST

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

RHHBYRoche Holdings AG2026-10-10 21:40 EST

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

RHHBYRoche Holdings AG2026-10-09 05:00 EST

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

Stock data

Close: 59.11 USD
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States